

Proposed Agency Procedure Regarding Litigation Brought Pursuant to 52 U.S.C. 30109(a)(8)
Management and Administrative Matters

CONTACT PERSON FOR MORE INFORMATION:
Judith Ingram, Press Officer. Telephone: (202) 694-1220.

Individuals who plan to attend in person and who require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Secretary and Clerk, at (202) 694-1040, at least 72 hours prior to the meeting date.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Laura E. Sinram,

Secretary and Clerk of the Commission.

[FR Doc. 2023-14309 Filed 6-30-23; 4:15 pm]

BILLING CODE 6715-01-P

FEDERAL MARITIME COMMISSION

Notice of Request for Additional Information

The Commission gives notice that it has formally requested that the parties to the below listed agreements provide additional information pursuant to 46 U.S.C. 40304(d). This action prevents the agreements from becoming effective as originally scheduled. Interested parties may submit comments, relevant information, or documents regarding the agreements to the Secretary by email at Secretary@fmc.gov, or by mail, Federal Maritime Commission, 800 North Capitol Street, Washington, DC 20573. Comments may be filed up to fifteen (15) days after publication of this notice appears in the **Federal Register**.

Agreement No.: 201349-003.

Title: World Shipping Council Agreement.

Parties: COSCO Shipping Lines Co., Ltd., Orient Overseas Container Line Ltd., and OOCL (Europe) Limited (acting as a single party); CMA CGM S.A., APL Co. Pte. Ltd., American President Lines, LLC and ANL Singapore Pte Ltd. (acting as a single party); Crowley Caribbean Services, LLC and Crowley Latin America Services, LLC (acting as a single party); Evergreen Marine Corporation (Taiwan) Ltd.; Hapag-Lloyd AG; HMM Company Limited; Independent Container Line, Ltd.; Kawasaki Kisen Kaisha Ltd., Maersk A/S and Hamburg Sud (acting as a single party); Matson Navigation Company, Inc.; MSC Mediterranean Shipping Company SA; Mitsui O.S.K. Lines Ltd.; Nippon Yusen Kaisha; Ocean Network Express Pte. Ltd.; Swire

Shipping, Pte. Ltd.; Wallenius Wilhelmsen Ocean AS; Wan Hai Lines Ltd. and Wan Hai Lines (Singapore) Pte Ltd. (acting as a single party); Yang Ming Marine Transport Corp.; and Zim Integrated Shipping Services, Ltd.

By Order of the Federal Maritime Commission

Dated: June 29, 2023.

JoAnne O'Bryant,

Program Analyst.

[FR Doc. 2023-14134 Filed 7-3-23; 8:45 am]

BILLING CODE 6730-02-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than August 4, 2023.

A. Federal Reserve Bank of San Francisco: (Joseph Cuenco, Assistant Vice President, Formations, Transactions and Enforcement) 101 Market Street, San Francisco, California 94105-1579. Comments can also be sent electronically to: sf.fisc.comments.applications@sf.frb.org.

1. *Bancorp 34, Inc., Scottsdale, Arizona;* to acquire CBOA Financial, Inc., and thereby indirectly acquire Commerce Bank of Arizona, Inc., both of Tucson, Arizona.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2023-14162 Filed 7-3-23; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Breastfeeding and Health Outcomes for Infants and Children

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submissions.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Breastfeeding and Health Outcomes for Infants and Children*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: *Submission Deadline* on or before August 4, 2023.

ADDRESSES:

Email submissions: epc@ahrq.hhs.gov

Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656 or Email: epc@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the

evidence for *Breastfeeding and Health Outcomes for Infants and Children*. AHRQ is conducting this systematic review pursuant to section 902 of the Public Health Service Act, 42 U.S.C. 299a.

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Breastfeeding and Health Outcomes for Infants and Children, including those that describe adverse events. The entire research protocol is available online at: <https://effectivehealthcare.ahrq.gov/products/breastfeeding-health-outcomes/protocol>.

This is to notify the public that the EPC Program would find the following information on Breastfeeding and Health Outcomes for Infants and Children helpful:

■ A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number*.

■ *For completed studies that do not have results on ClinicalTrials.gov*, a summary, including the following

elements: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.

■ *A list of ongoing studies that your organization has sponsored for this indication*. In the list, please provide the *ClinicalTrials.gov* trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

■ Description of whether the above studies constitute *ALL Phase II and above clinical trials* sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying

with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at:

<https://www.effectivehealthcare.ahrq.gov/email-updates>.

The systematic review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.

Key Questions (KQ)

This review will be guided by one Key Question (KQ 1) that addresses the infant and child health outcomes associated with breastfeeding and consuming human milk. One sub-KQ (KQ 1a) addresses variation in the associations by important variables related to breastfeeding and human milk consumption.

1. What is the association between breastfeeding/human milk consumption and health outcomes among infants and children?

a. How do these associations vary by intensity (including exclusivity), duration, and mode of feeding, and by source of human milk?

POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY DESIGN (PICOTS)

PICOTS	Inclusion	Exclusion
Populations	Full term infants (≥ 37 and 0/7 weeks gestation) • Preterm (gestational age < 37 weeks) infants^a. • Low birth weight (< 2500 grams) or small for gestational age infants. • Women with medical conditions contraindicated for breastfeeding (e.g., breast cancer, HIV).	Studies exclusively among:
Exposures	Any exposure to human milk, including feeding at the breast; consuming expressed human milk; or a combination.	Application of human milk to skin
Comparators	• No exposure to human milk • Less intensive exposure (e.g., mixed feeding or commercial milk formula consumption vs. exclusive consumption; lower proportion of feedings that are human milk). • Shorter duration of exposure. • Different mechanism of exposure (e.g., feeding at the breast [direct breastfeeding] vs. feeding expressed human milk). • Different source of human milk (e.g., milk from lactating parent vs. milk from donor).	All other comparisons; no comparison.
Outcomes ^b	Health outcomes observed at any point in the life course, specifically: • Allergies, specifically: ○ Atopic dermatitis. ○ Allergic rhinitis. ○ Food allergies. • Asthma. • Celiac disease. • Cognitive development (e.g., measures of IQ and other cognitive development measures). • Childhood cancer. • Cardiovascular disease outcomes, specifically:	Any other outcome not specified, including maternal health outcomes.

POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY DESIGN (PICOTS)—Continued

PICOTS	Inclusion	Exclusion
	○ Blood lipid levels, hyperlipidemia. ○ Blood pressure, elevated blood pressure. ○ Arterial stiffness, intima-media thickness, atherosclerosis. ○ Metabolic syndrome. ○ Incidence and prevalence of CVD. ○ CVD-related mortality. ● Diabetes, specifically: ○ Type I. ○ Type II. ● Infectious diseases, specifically: ○ Otitis media. ○ Diarrhea/GI infection. ○ Upper and lower respiratory tract infections including COVID-19. ● Oral health outcomes, specifically: ○ Dental caries. ○ Malocclusions. ● Sudden infant death syndrome/sudden unexpected infant death. ● Infant mortality. ● Inflammatory bowel disease. ● Weight-related outcomes, specifically: ○ Weight gain velocity (birth to 24 months). ○ Obesity.	
Country setting	Studies conducted in a more developed country, defined as “very high” on the 2021 human development index per the United Nations Development Programme ⁴⁴ .	Studies conducted in other countries.
Study designs	● Existing systematic reviews^c ● Observational studies comparing health outcomes among 2 or more groups with different exposures to human milk, including cohort and case-control^d studies and studies with observational follow-up of health outcomes from randomized or non-randomized clinical trials of breastfeeding support interventions.	All other designs, including: ● Studies of breastfeeding support interventions without observational follow-up of health outcomes. ● Studies with no comparison groups. ● Cross-sectional studies.^e ● Case series.
Publication language	Studies published in English	Studies published in languages other than English.

Abbreviations: ADHD = attention deficit hyperactivity disorder; ASD = autism spectrum disorder; COVID-19 = coronavirus disease 2019; GI = gastrointestinal; HIV = human immunodeficiency virus; NICU = neonatal intensive care unit.

^a The full report will contextually consider the unique feeding needs of this population and will discuss what we know about the association between breastfeeding and health outcomes for preterm infants. This evidence will not be systematically reviewed.

^b The full report will contextually discuss potentially harmful unintended consequences related to breastfeeding such as excessive weight loss, hyperbilirubinemia, and hypoglycemia. This evidence will not be systematically reviewed.

^c Well-conducted systematic review, with or without meta-analysis, that aligns with these PICOTS criteria and is not rated as “critically low” according to systematic review credibility criteria using AMSTAR 2.⁴⁵

^d Case-control studies will be considered only in cases in which the outcome is rare (<1/1000) and/or this is the only evidence available for that particular outcome.

^e Cross-sectional studies will be excluded except in cases in which the study compares outcomes between twins or siblings with different exposures.

Dated: June 29, 2023.

Marquita Cullom,

Associate Director.

[FR Doc. 2023-14184 Filed 7-3-23; 8:45 am]

BILLING CODE 4160-90-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Solicitation of Nominations for Appointment to the Board of Scientific Counselors, National Center for Injury Prevention and Control

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC). The BSC, NCIPC consists of up to 18 experts in pertinent disciplines involved in injury and violence prevention.

DATES: Nominations for membership on the BSC, NCIPC must be received no later than September 15, 2023. Packages received after this time will not be considered for the current membership cycle.

ADDRESSES: All nominations should be emailed to ncipcbcs@cdc.gov.

FOR FURTHER INFORMATION CONTACT:

Christopher R. Harper, Ph.D., Designated Federal Officer, Board of Scientific Counselors, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S-1069, Atlanta, Georgia 30341. Telephone: (404) 718-8330. Email: ncipcbcs@cdc.gov.

SUPPLEMENTARY INFORMATION:

Nominations are sought for individuals who have expertise and qualifications necessary to contribute to the accomplishment of the objectives of the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC). Nominees will be